Suchergebnisse - "Gupta, Neeraj"

PubPharm (29)

11

Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor : Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Analysis

enthalten in: Journal of clinical pharmacology | 2018

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +13

12

A Phase 1 Study to Assess the Relative Bioavailability of Two Capsule Formulations of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2018

von Hanley, M. | Gupta, N. | Venkatakrishnan, K. | +6

13

Population Pharmacokinetic Analysis of Ixazomib, an Oral Proteasome Inhibitor, Including Data from the Phase III TOURMALINE-MM1 Study to Inform Labelling

enthalten in: Clinical pharmacokinetics | 2017

von Gupta, N. | Diderichsen, P. | Hanley, M. | +4

14

Dose and Schedule Selection of the Oral Proteasome Inhibitor Ixazomib in Relapsed/Refractory Multiple Myeloma : Clinical and Model-Based Analyses

enthalten in: Targeted oncology | 2017

von Gupta, N. | Yang, H. | Hanley, M. | +6

15

Management of adverse events associated with ixazomib plus lenalidomide/dexamethasone in relapsed/refractory multiple myeloma

enthalten in: British journal of haematology | 2017

von Kumar, S. | Moreau, P. | Hari, P. | +17

16

A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis

enthalten in: Blood | 2017

von Sanchorawala, V. | Palladini, G. | Kukreti, V. | +12

ErratumIn: Blood. 2020 Mar 26;135(13):1071. - PMID 32219354

17

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma : China Continuation study

enthalten in: Journal of hematology & oncology | 2017

von Hou, J. | Jin, J. | Xu, Y. | +18

18

The Effect of a High-Fat Meal on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor, in Patients With Advanced Solid Tumors or Lymphoma

enthalten in: Journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +5

19

Pharmacokinetics of ixazomib, an oral proteasome inhibitor, in solid tumour patients with moderate or severe hepatic impairment

enthalten in: British journal of clinical pharmacology | 2016

von Gupta, N. | Hanley, M. | Venkatakrishnan, K. | +8

20

A pharmacokinetics and safety phase 1/1b study of oral ixazomib in patients with multiple myeloma and severe renal impairment or end-stage renal disease requiring haemodialysis

enthalten in: British journal of haematology | 2016

von Gupta, N. | Hanley, M. | Harvey, R. | +10